Eton Pharmaceuticals Enters Material Definitive Agreement
Ticker: ETON · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1710340
Sentiment: neutral
Topics: material-agreement
TL;DR
Eton Pharma just signed a big deal, details TBD.
AI Summary
Eton Pharmaceuticals, Inc. announced on November 22, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement, the counterparty, or any associated financial figures. Further information is expected to be provided in subsequent filings.
Why It Matters
This filing indicates a significant new development for Eton Pharmaceuticals, potentially impacting its business strategy and future financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in this 8-K filing creates uncertainty about the nature and implications of the material definitive agreement.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- November 22, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Eton Pharmaceuticals?
The filing does not specify the nature of the material definitive agreement.
Who is the counterparty to the material definitive agreement?
The filing does not disclose the identity of the counterparty to the agreement.
Are there any financial terms or obligations associated with this agreement disclosed in the filing?
No, the filing does not provide any specific financial terms or dollar amounts related to the agreement.
When was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is November 22, 2024.
What is the primary business of Eton Pharmaceuticals, Inc. according to the filing?
Eton Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, with SIC code 2834.
Filing Stats: 631 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-11-25 07:00:10
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
- $2.35 million — payments to Seller and could pay up to $2.35 million as follows: $0.50 million following th
- $0.50 million — ld pay up to $2.35 million as follows: $0.50 million following the receipt of FDA meeting mi
- $0.55 million — ng the receipt of FDA meeting minutes $0.55 million upon NDA acceptance for review by the F
- $1.30 million — NDA acceptance for review by the FDA $1.30 million upon NDA approval by the FDA and first
Filing Documents
- eton20241117_8k.htm (8-K) — 29KB
- ex_749253.htm (EX-99.1) — 11KB
- 0001437749-24-036095.txt ( ) — 173KB
- eton-20241122.xsd (EX-101.SCH) — 3KB
- eton-20241122_def.xml (EX-101.DEF) — 11KB
- eton-20241122_lab.xml (EX-101.LAB) — 15KB
- eton-20241122_pre.xml (EX-101.PRE) — 11KB
- eton20241117_8k_htm.xml (XML) — 3KB
01: Entry into a Material Definitive Agreement
Item 1.01: Entry into a Material Definitive Agreement On November 22, 2024, Eton Pharmaceuticals, Inc. (the "Company") entered into a Licensing Agreement (the "Licensing Agreement") with AMMTeK. (the "Seller"), pursuant to which the Company has agreed to acquire the U.S. rights to Amglidia (glyburide oral suspension) from the Seller. Amglidia is being developed for the treatment of neonatal diabetes mellitus, a rare condition estimated to impact approximately 300 patients in the U.S. The product was approved by the European Medicines Agency in 2018 and has been granted Orphan Drug Designation by the U.S. FDA. The Seller has conducted a post-approval study tracking five years of real-world safety and efficacy in European patients, which will be used to support Eton's New Drug Application ("NDA") submission. The Company intends to hold a meeting with the FDA in the first quarter of 2025 and retains the option to terminate the licensing agreement within 30 days of receiving FDA meeting minutes without liability for any milestone payments to the Seller. Under the terms of the Licensing Agreement, the Company will not make any upfront payments to Seller and could pay up to $2.35 million as follows: $0.50 million following the receipt of FDA meeting minutes $0.55 million upon NDA acceptance for review by the FDA $1.30 million upon NDA approval by the FDA and first commercial sale In addition, the Company would pay a royalty of 14% of net sales to the Seller. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 99.1 Press Release dated November 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 25, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4